自身免疫性疾病药物市场
自身免疫性疾病药物市场：2026年市场规模约为1197.3亿美元，2031年市场规模约为1550亿美元；预测期复合年增长率为5.30%；当前最大市场为北美；增长最快的市场为亚太地区。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
自身免疫性疾病药物市场：2026年市场规模约为1197.3亿美元，2031年市场规模约为1550亿美元；预测期复合年增长率为5.30%；当前最大市场为北美；增长最快的市场为亚太地区。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 5.3% | 机构预测 |
| 市场规模 | 2026 | USD 119.73 billion | 机构预测 |
| 市场规模 | 2031 | USD 155 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| disease_indication | rheumatoid arthritis | 2025 | 46.930% |
| drug_class | NSAIDs | 2025 | 34.560% |
| end_user | hospitals | 2025 | 52.670% |
| formulation | tablets and capsules | 2025 | 45.780% |
| geography | North America | 2025 | 38.670% |
| route_of_administration | oral products | 2025 | 61.450% |
关键结论
- disease_indication 维度中，rheumatoid arthritis 在 2025 年的公开份额为 46.93%。
- drug_class 维度中，NSAIDs 在 2025 年的公开份额为 34.56%。
- end_user 维度中，hospitals 在 2025 年的公开份额为 52.67%。
- formulation 维度中，tablets and capsules 在 2025 年的公开份额为 45.78%。
- geography 维度中，North America 在 2025 年的公开份额为 38.67%。
- route_of_administration 维度中，oral products 在 2025 年的公开份额为 61.45%。
主要参与者
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
- Novartis AG
- Pfizer Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising prevalence and earlier diagnosis of autoimmune diseases | +1.800% | Global, with acute effects in North America and Western Europe | Long term (≥ 4 years) |
| Expansion of biologic and targeted synthetic therapies | +1.500% | North America and Europe, with growth in Asia-Pacific and selected Middle East and Africa markets | Medium term (2-4 years) |
| Increasing treatment adoption in emerging markets | +1.000% | Asia-Pacific, with spillover to Middle East and Africa and South America | Long term (≥ 4 years) |
| Expansion of indications for established immunology products | +0.800% | North America and Europe, with accelerating Asia-Pacific adoption | Short term (≤ 2 years) |
| Precision immunology through biomarker and patient stratification | +0.500% | North America and Europe, with clinical trial activity in Asia-Pacific | Medium term (2-4 years) |
| Growth of self-administration and home-based treatment | +0.400% | North America, with growing adoption in Western Europe | Short term (≤ 2 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| High cost of biologic development and long clinical timelines | -0.900% | Global, with the strongest effect in markets without public research and development support | Long term (≥ 4 years) |
| Biosimilar competition and loss of exclusivity | -0.800% | North America and Europe, with later pressure in Asia-Pacific and Middle East and Africa | Short term (≤ 2 years) |
| Fragmented diagnosis and delayed referral across autoimmune diseases | -1.500% | Global, particularly acute in Asia-Pacific and South America | Long term (≥ 4 years) |
| Long-term safety, immunogenicity, and treatment-persistence concerns | -1.200% | North America and Western Europe | Medium term (2-4 years) |
报告关注的关键问题
What is the projected value of autoimmune drugs in 2031?
The autoimmune drugs market is projected to reach USD 155.00 billion by 2031, rising from USD 119.73 billion in 2026 at a 5.30% CAGR. Growth reflects earlier diagnosis, targeted therapies, and broader product labels.
Which drug class held the largest share in 2025?
NSAIDs led drug classes with 34.56% share in 2025. Their broad use, affordability, and established role as foundational or adjunctive treatment support continued demand across several autoimmune conditions.
Which autoimmune disease indication is growing fastest?
Multiple sclerosis is forecast to grow at an 8.80% CAGR through 2031. New treatment approaches, including CNS-penetrant BTK inhibitors, are supporting activity in progressive neurological disease.
Why are biosimilars important for autoimmune treatment?
Biosimilars can expand treatment access and reduce originator pricing, especially in mature TNF inhibitor categories. They also shift competition toward supply reliability, distribution, and patient-support services.
Which delivery route is expected to grow fastest?
Intravenous delivery is forecast to grow at a 7.45% CAGR through 2031 because it remains important for complex and severe disease. Ambulatory and home infusion settings may widen access for appropriate patients.
Which region is forecast to grow fastest through 2031?
Asia-Pacific is forecast to grow at a 9.58% CAGR through 2031. Biologics manufacturing, clinical infrastructure, and biosimilar development in China, India, and South Korea are supporting this expansion.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence